Avelumab plus axitinib combination available via EAMS
It has just been announced that the avelumab plus axitinib [...]
Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer
A recent study, published in Clinical Genitourinary Cancer reports a [...]
Nivolumab and kidney cancer brain metastases
Results from a recent trial suggest that nivolumab has limited [...]
Mucinous tubular and spindle cell carcinoma
A recent study, published in Clinical Genitourinary Cancer, looked at [...]
Obesity now leading cause of four cancers
Cancer Research UK has released new findings showing that carrying [...]
Role of stereotactic ablative radiotherapy (SABR) for kidney cancer
This systematic review and meta-analysis of the literature for the [...]
ASCO 2019: Safety and efficacy of immune checkpoint inhibitors in patients with pre-existing autoimmune disorders
This study was presented at the American Society of Clinical [...]
Current perspectives on non-clear cell kidney cancer
The majority of kidney cancer (around 80%) is characterised as [...]
Scientists discover molecular key to how cancer spreads
Scientists at Yale University in America have discovered the molecular [...]
Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer
Telaglenastat is an oral glutaminase inhibitor and this is the [...]
